Brendstrup L, Hjelt K, Petersen K E, Petersen S, Andersen E A, Daugbjerg P S, Stagegaard B R, Nielsen O H, Vejlsgaard R, Schou G
Department of Paediatrics, Hillerød Hospital, University of Copenhagen, Denmark.
Acta Paediatr Scand. 1990 Dec;79(12):1225-34. doi: 10.1111/j.1651-2227.1990.tb11414.x.
The efficiency of nitrofurantoin and trimethoprim prophylaxis in preventing recurrent urinary tract infections (UTI) was compared by means of actuarial percentage recurrence-free curves in a randomized, double blind study in 130 children (126 girls, 4 boys) aged 1 to 14 years (mean 7.5). The children received the antibiotics for 6 months. Nitrofurantoin proved to be the most efficient prophylactic drug in patients with abnormal urography and/or reflux (n = 60) as evaluated by actuarial percentage recurrence-free analysis (p = 0.0025). However, no differences was found in patients without urinary tract abnormalities. Nitrofurantoin prophylaxis altered neither the pattern of resistance nor the bacteriological constellation, while patients receiving trimethoprim prophylaxis had 76% trimethoprim resistant bacteria during prophylaxis, compared with 8% before (p less than 0.0001) and 17% after (p less than 0.0001) prophylaxis. The percentage of recurrences due to E. coli (70-80%) was unaffected by trimethoprim prophylaxis, but the proportion due to trimethoprim resistant E. coli was significantly higher during prophylaxis (65%) than before (6%, p less than 0.0001) and after (11%, p less than 0.001). The percentage of Staphylococcus epidermidis UTI was significantly higher during trimethoprim prophylaxis (27%) than before (2%, p less than 0.0003). Following prophylaxis there was no difference in the actuarial percentage recurrence-free curves of the two regimens. Side effects occurred more frequently in the nitrofurantoin group (37%) than in the trimethoprim group (21%) (p = 0.05). The majority of side effects in the nitrofurantoin group derived from gastrointestinal symptoms. In conclusion, nitrofurantoin is recommended as the first choice prophylactic treatment of children with recurrent UTI and urinary tract abnormalities.
在一项针对130名年龄在1至14岁(平均7.5岁)儿童(126名女孩,4名男孩)的随机双盲研究中,通过精算无复发百分比曲线比较了呋喃妥因和甲氧苄啶预防复发性尿路感染(UTI)的效果。这些儿童接受抗生素治疗6个月。通过精算无复发百分比分析评估,呋喃妥因被证明是尿路造影异常和/或反流患者(n = 60)中最有效的预防性药物(p = 0.0025)。然而,在无尿路异常的患者中未发现差异。呋喃妥因预防既未改变耐药模式,也未改变细菌学构成,而接受甲氧苄啶预防的患者在预防期间有76%的细菌对甲氧苄啶耐药,相比之下,预防前为8%(p < 0.0001),预防后为17%(p < 0.0001)。由大肠杆菌引起的复发百分比(70 - 80%)不受甲氧苄啶预防的影响,但在预防期间由耐甲氧苄啶大肠杆菌引起的比例显著高于预防前(6%,p < 0.0001)和预防后(11%,p < 0.001)。在甲氧苄啶预防期间,表皮葡萄球菌UTI的百分比显著高于预防前(2%,p < 0.0003)(27%)。预防后,两种治疗方案的精算无复发百分比曲线没有差异。呋喃妥因组的副作用发生率(37%)高于甲氧苄啶组(21%)(p = 0.05)。呋喃妥因组的大多数副作用源于胃肠道症状。总之,呋喃妥因被推荐作为复发性UTI和尿路异常儿童的首选预防性治疗药物。